EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Amira Drug Gets Orphan Status

The U.S. Food and Drug Administration has granted orphan drug designation to AM152, the lead drug candidate under development at San Diego’s Amira Pharmaceuticals for treating idiopathic pulmonary fibrosis, a lung disease that makes it difficult to breathe. In a statement yesterday, the company says the designation provides a seven-year period of market exclusivity and potential tax credits and regulatory advantages to the developer of a new drug therapy for diseases that affect fewer than 200,000 people in the United States. Amira says it is completing early stage tests of a compound that seems to help block the activation of a cellular receptor implicated in tissue fibrosis and related disease processes.

By posting a comment, you agree to our terms and conditions.

  • Lowetta Jouppi

    I just read the article & hope you hurry & make it available……..I would really like a treatment that works!
    Good luck.